Fosun Pharmaceutical's US $83.5 million large transaction layout in the domestic kidney disease Market

Fosun Pharmaceutical issued a notice on February 15, saying that its holding subsidiary Shanghai kaimao biomedical Co., Ltd (kaimao bio) signed an agreement with Korean genexine company to obtain the commercial rights of anaemic drug gx-e2 injection in China, and paid a license fee of no more than 44.5 million US dollars (technology transfer fee)+ R & D and sales milestone payment) In addition, Kemo biology shall pay genexine the sales share based on the actual sales volume of the product according to the agreed time and proportion   On February 16, Rockwell Medical Co., Ltd of the United States announced that it had signed an exclusive license and production supply agreement with Jiangsu Wanbang Biochemical Medicine Co., Ltd (Wanbang medicine), a subsidiary of Fosun Pharmaceutical, with a total amount of US $39 million (advance payment + supervision and sales mileage Fund), which would give exclusive commercial rights to two kidney disease drugs, triferic (pyrophosphate) and calcitriol (calcitriol), in China License to Wanbang medicine Wanbang pharmaceutical independently undertakes the clinical development, regulatory registration and commercial promotion costs of triferic and calcitriol in China, and will become the exclusive distributor of these two drugs in China for 10 years; if Wanbang pharmaceutical reaches the minimum annual purchase demand, it can also obtain an additional 10 years or more exclusive distribution rights Rockwell also has the right to receive a share from WBM based on sales (existing indications and new indications) Gx-e2 injection is a long-acting erythropoietin Fc fusion protein Currently, phase II clinical research is being carried out in South Korea Kaimao biology has obtained the commercial rights of gx-e2 in China (excluding Taiwan, Hong Kong and Macao), and will be responsible for the clinical development, registration, listing, production and commercial promotion of gx-e2 in chronic renal failure, anemia caused by chemotherapy and other indications Triferic is Rockwell's proprietary iron ion replacement therapy, which was approved by FDA on January 23, 2015 for the treatment of iron loss in patients with chronic kidney disease dialysis In addition to the indications of hemodialysis, Wanbang pharmaceutical has the right to develop new indications of triferic based on the Chinese market, and the relevant costs shall be borne by Wanbang pharmaceutical independently Calcitriol is a generic (active biotin D injection) for the treatment of secondary hyperparathyroidism Secondary hyperparathyroidism (SHPT) can occur in the early stage of chronic renal insufficiency, which leads to renal osteodystrophy and high transformation renal osteopathy The two main causes of SHPT are hypocalcemia and the lack of calcitriol (active biotin d) The main treatment is to supplement calcitriol The stable layout of the domestic kidney disease market The purchase of a phase II long-acting EPO drug by kaimao biology for us $44.5 million once puzzled the outside world In addition to the transaction price being considered to be too expensive, there are also development risks for gx-e2 Because according to the relevant requirements of new drug research and development in China, gx-e2 products still need to carry out phase I, phase II and / or phase III clinical trials in China and pass the CFDA approval before being put on the market However, with the disclosure of Wanbang pharmaceutical's purchase of two more mature nephrotic drugs for $39 million, Fosun Pharmaceutical's idea of laying out China's nephrotic market with the help of these two $83.5 million transactions is becoming clear Fosun Pharmaceutical pointed out in the announcement that the EPO products for chronic renal failure and anemia caused by chemotherapy in the Chinese market are ordinary EPO products, and there are no long-term EPO products on the market Common EPO products have the disadvantages of frequent administration, large fluctuation of patients' red blood cells, and easy to cause thrombus and other adverse consequences The cooperation with genexine company of South Korea will help Fosun to expand the domestic EPO product market, make up the gap of long-term EPO product in China market, so as to effectively serve related patients According to imsmidas, from January to September 2015, the sales volume of general EPO products in the Chinese market was about 1.3 billion yuan There are about 300000 hemodialysis patients in China, and the market is expected to double in the next few years For the deal with Rockwell, Wu Yifang, CFO of Fosun Pharmaceutical and CEO of Wanbang pharmaceutical, said: "we are excited to be able to provide these two excellent drugs to the Chinese hemodialysis market and develop other indications of triferic in the Chinese market Triferic is a revolutionary iron ion replacement drug, which can significantly improve the quality of life of hemodialysis patients Wanbang is committed to meeting the broad needs of patients and medical institutions for hemodialysis in different places such as families, treatment centers or hospitals Rockwell's high-quality drugs are conducive to expanding Wanbang's product line in the field of kidney disease "